[go: up one dir, main page]

HRP20100673T1 - Smanjivanje potencijalnih jatrogenskih rizika povezanih s cjepivima protiv gripe - Google Patents

Smanjivanje potencijalnih jatrogenskih rizika povezanih s cjepivima protiv gripe Download PDF

Info

Publication number
HRP20100673T1
HRP20100673T1 HR20100673T HRP20100673T HRP20100673T1 HR P20100673 T1 HRP20100673 T1 HR P20100673T1 HR 20100673 T HR20100673 T HR 20100673T HR P20100673 T HRP20100673 T HR P20100673T HR P20100673 T1 HRP20100673 T1 HR P20100673T1
Authority
HR
Croatia
Prior art keywords
virus
vaccine
degree
culture
family
Prior art date
Application number
HR20100673T
Other languages
English (en)
Inventor
Gregersen Jens-Peter
Original Assignee
Novartis Vaccines And Diagnostics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35520177&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20100673(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Vaccines And Diagnostics Gmbh filed Critical Novartis Vaccines And Diagnostics Gmbh
Publication of HRP20100673T1 publication Critical patent/HRP20100673T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/11—Orthomyxoviridae, e.g. influenza virus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)

Abstract

Postupak za pripremanje cjepiva protiv gripe iz virusa gripe izraslog u kulturi Vero stanične linije, koji sadrži stupanj u kojem se uzgojeni virus i/ili cjepivo i/ili kultura testira na prisutnost infekcijskog agensa koji može rasti u navedenoj staničnoj liniji, ali koji ne raste u embriju kokošjih jaja, naznačen time, da je navedeni infekcijski agens jedan ili više od sljedećih patogena: Pneumovirinae; Metapneumovirusi iz familije Paramyxoviridae; Rubulavirusi iz familije Paramyxoviridae; Coronaviridae; Rhinovirusi iz familije Picornaviridae; Varicella Zoster virus; BK polyomavirus, JC polyomavirus; Echovirusi; Coxsackievirusi od Enterovirusa iz familije Picornaviridae; Rotavirus, svinjski picornavirusi; Parvovirus; Circovirus; bakterija Chlamydia; Reoviridae kod sisavaca. Patent sadrži još 5 patentnih zahtjeva.

Claims (6)

1. Postupak za pripremanje cjepiva protiv gripe iz virusa gripe izraslog u kulturi Vero stanične linije, koji sadrži stupanj u kojem se uzgojeni virus i/ili cjepivo i/ili kultura testira na prisutnost infekcijskog agensa koji može rasti u navedenoj staničnoj liniji, ali koji ne raste u embriju kokošjih jaja, naznačen time, da je navedeni infekcijski agens jedan ili više od sljedećih patogena: Pneumovirinae; Metapneumovirusi iz familije Paramyxoviridae; Rubulavirusi iz familije Paramyxoviridae; Coronaviridae; Rhinovirusi iz familije Picornaviridae; Varicella Zoster virus; BK polyomavirus, JC polyomavirus; Echovirusi; Coxsackievirusi od Enterovirusa iz familije Picornaviridae; Rotavirus, svinjski picornavirusi; Parvovirus; Circovirus; bakterija Chlamydia; Reoviridae kod sisavaca.
2. Postupak prema patentnom zahtjevu 1, naznačen time, da infekcijski agens jest jedan ili više od sljedećih patogena: humani metapneumovirus (HMPV); virus mumpsa; respiratorni sincicijski virus (RSV); humani coronavirusi; SARS corona virus; M sojevi Rhinovirusa; svinjski vezikularni virus (SVDV); pseći Parovirus, Teschen-Talfan virus; C. trachomatis; C. pneumoniae; C. psittaci.
3. Postupak prema patentnom zahtjevu 1, naznačen time, da nadalje sadrži jedan ili više od sljedećih stupnjeva: stupanj inaktivacije; stupanj miješanja tri virusna soja da se napravi trovalentno cjepivo; stupanj formuliranja cjepiva za injektiranje; stupanj združivanja cjepiva s adjuvansom; stupanj mjerenja sadržaja HA; stupanj podešavanja sadržaja HA, na pr. razrjeđivanjem; stupanj dodavanja konzervansa; stupanj odstranjivanja rezidualnih nukleinskih kiselina koje pripadaju stanici domaćina.
4. Postupak prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time, da se kultura testira imunokemijskom detekcijom; testovima inokulacije stanične kulture i/ili detekcijom nukleinske kiseline.
5. Postupak prema patentnom zahtjevu 4, naznačen time, da se detekcija provodi metodom ELISA i/ili PCR.
6. Postupak prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time, da se testiranje provodi kod jednog od sljedećih stupnjeva: virusna infekcija, stadiji rasta, prikupljanje virusa, procesuiranje virusa, razdvajanje, ekstrakcija membranskih proteina, formuliranje cjepiva, pakiranje cjepiva.
HR20100673T 2004-09-09 2005-09-09 Smanjivanje potencijalnih jatrogenskih rizika povezanih s cjepivima protiv gripe HRP20100673T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04255471 2004-09-09
PCT/IB2005/003266 WO2006027698A1 (en) 2004-09-09 2005-09-09 Decreasing potential iatrogenic risks associated with influenza vaccines

Publications (1)

Publication Number Publication Date
HRP20100673T1 true HRP20100673T1 (hr) 2011-02-28

Family

ID=35520177

Family Applications (4)

Application Number Title Priority Date Filing Date
HR20100673T HRP20100673T1 (hr) 2004-09-09 2005-09-09 Smanjivanje potencijalnih jatrogenskih rizika povezanih s cjepivima protiv gripe
HR20110007T HRP20110007T1 (hr) 2004-09-09 2011-01-05 Smanjivanje potencijalnih jatrogenskih rizika povezanih s cjepivima protiv gripe
HRP20120640TT HRP20120640T1 (hr) 2004-09-09 2012-08-07 Smanjenje potencijalnih jatrogenih rizika vezanih uz cjepiva protiv gripe
HRP20130962TT HRP20130962T1 (hr) 2004-09-09 2013-10-10 Smanjenje potencijalnih iatrogenih rizika povezanih sa antigenima cjepiva

Family Applications After (3)

Application Number Title Priority Date Filing Date
HR20110007T HRP20110007T1 (hr) 2004-09-09 2011-01-05 Smanjivanje potencijalnih jatrogenskih rizika povezanih s cjepivima protiv gripe
HRP20120640TT HRP20120640T1 (hr) 2004-09-09 2012-08-07 Smanjenje potencijalnih jatrogenih rizika vezanih uz cjepiva protiv gripe
HRP20130962TT HRP20130962T1 (hr) 2004-09-09 2013-10-10 Smanjenje potencijalnih iatrogenih rizika povezanih sa antigenima cjepiva

Country Status (15)

Country Link
US (6) US8119337B2 (hr)
EP (5) EP1789084B1 (hr)
JP (7) JP2008512443A (hr)
AT (2) ATE489965T1 (hr)
CA (2) CA2890962A1 (hr)
CY (3) CY1111180T1 (hr)
DE (3) DE12193096T1 (hr)
DK (4) DK2236155T3 (hr)
ES (4) ES2432655T3 (hr)
HR (4) HRP20100673T1 (hr)
PL (4) PL2236155T3 (hr)
PT (4) PT2179744E (hr)
RS (3) RS51665B (hr)
SI (4) SI1789084T1 (hr)
WO (1) WO2006027698A1 (hr)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008512443A (ja) 2004-09-09 2008-04-24 カイロン ベーリング ゲーエムベーハー アンド カンパニー インフルエンザワクチンに関連する潜在的医原性リスクの減少
ES2310062B1 (es) 2005-07-15 2009-11-13 Bionostra, S.L. Particulas pseudovirales vacias quimericas derivadas del virus causante de la enfermedad de la bursitis infecciosa (ibdv), procedimiento de obtencion y aplicaciones.
EP1951296B2 (en) * 2005-11-01 2014-07-23 Novartis Vaccines and Diagnostics GmbH Cell-derived viral vaccines with low levels of residual cell dna by beta-propiolactone treatment
AU2006310339B2 (en) 2005-11-04 2013-01-10 Novartis Ag Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
EA014028B1 (ru) 2005-11-04 2010-08-30 Новартис Вэксинс Энд Диагностикс Срл Эмульсии, содержащие свободное поверхностно-активное вещество в водной фазе в качестве адъюванта сплит вакцин против гриппа
NZ594482A (en) 2005-11-04 2012-11-30 Novartis Vaccines & Diagnostic Influenza vaccines with reduced amount of oil-in-water emulsion as adjuvant
AU2006310337B9 (en) 2005-11-04 2013-11-28 Novartis Ag Adjuvanted influenza vaccines including cytokine-inducing agents
PL2368572T3 (pl) 2005-11-04 2020-11-16 Seqirus UK Limited Szczepionki z adjuwantem z niewirionowymi antygenami otrzymane z wirusów grypy hodowanych w hodowli komórkowej
EP2478916B1 (en) 2006-01-27 2020-04-01 Seqirus UK Limited Influenza vaccines containing hemagglutinin and matrix proteins
JP2009534303A (ja) 2006-03-24 2009-09-24 ノバルティス ヴァクシンズ アンド ダイアグノスティクス ゲーエムベーハー アンド カンパニー カーゲー 冷蔵しないインフルエンザワクチンの保存
JP2009532352A (ja) 2006-03-31 2009-09-10 ダブリュエーアールエフ−ウィスコンシン アラムナイ リサーチ ファウンデーション ワクチンのための高力価組み換えインフルエンザ・ウィルス
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
BRPI0716536A2 (pt) 2006-09-11 2013-09-24 Novartis Ag produÇço de vacinas de vÍrus influenza, sem a utilizaÇço de ovos
WO2008059018A2 (en) * 2006-11-15 2008-05-22 Intervet International B.V. Vaccine for vaccinating felines and canines against influenza virus
EP2121011B1 (en) 2006-12-06 2014-05-21 Novartis AG Vaccines including antigen from four strains of influenza virus
US9474798B2 (en) 2007-06-18 2016-10-25 Wisconsin Alumni Research Foundation Influenza M2 protein mutant viruses as live influenza attenuated vaccines
CN101784283A (zh) 2007-06-27 2010-07-21 诺华有限公司 低添加流感疫苗
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
JP5518041B2 (ja) 2008-03-18 2014-06-11 ノバルティス アーゲー インフルエンザウイルスワクチン抗原の調製における改良
JP2012507272A (ja) 2008-11-05 2012-03-29 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 新規な方法
KR20110132373A (ko) 2009-02-10 2011-12-07 노파르티스 아게 유행병-연관 주에 대한 인플루엔자 백신 요법
EA023662B1 (ru) 2009-02-10 2016-06-30 Новартис Аг Вакцины против гриппа со сниженным количеством сквалена
CA2752041A1 (en) 2009-02-10 2010-08-19 Novartis Ag Influenza vaccines with increased amounts of h3 antigen
USH2283H1 (en) 2009-04-27 2013-09-03 Novartis Ag Vaccines for protecting against influenza
AU2010293902A1 (en) 2009-09-10 2012-03-22 Novartis Ag Combination vaccines against respiratory tract diseases
JP2013507990A (ja) 2009-10-26 2013-03-07 ダブリュエーアールエフ−ウィスコンシン アラムナイ リサーチ ファウンデーション ベロ細胞において増強された複製を有する高力価の組換えインフルエンザウイルス
US10130697B2 (en) 2010-03-23 2018-11-20 Wisconsin Alumni Research Foundation (Warf) Vaccines comprising mutant attenuated influenza viruses
CN102858961A (zh) * 2010-05-03 2013-01-02 葛兰素史密丝克莱恩生物有限公司 新方法
EP2571520B1 (en) 2010-05-21 2018-04-04 Seqirus UK Limited Influenza virus reassortment method
AU2011262309B2 (en) 2010-06-01 2015-08-13 Seqirus UK Limited Concentration of influenza vaccine antigens without lyophilization
CA2801151A1 (en) 2010-06-01 2011-12-08 Novartis Ag Concentration of vaccine antigens with lyophilization
GB201011502D0 (en) 2010-07-08 2010-08-25 Glaxosmithkline Biolog Sa Novel process
EP2605792B1 (en) 2010-08-20 2014-12-10 Novartis AG Soluble needle arrays for delivery of influenza vaccines
WO2012032482A1 (en) 2010-09-07 2012-03-15 Novartis Ag Generic assays for detection of mammalian reovirus
WO2012114312A2 (en) 2011-02-25 2012-08-30 Novartis Ag Exogenous internal positive control
AU2012324398A1 (en) 2011-10-20 2014-05-01 Seqirus UK Limited Adjuvanted influenza B virus vaccines for pediatric priming
ES2564138T3 (es) * 2011-12-12 2016-03-18 Novartis Ag Ensayo para Hemaglutinina del virus de la influenza
GB201218195D0 (en) 2012-10-10 2012-11-21 Istituto Zooprofilattico Sperimentale Delle Venezie Composition
EP3022296B1 (en) 2013-07-15 2022-12-28 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses with enhanced replication in mdck or vero cells or eggs
BE1023557B1 (fr) 2014-02-10 2017-05-03 Univercells Sa Systeme, appareil et procede pour la production de biomolecules
RU2628800C2 (ru) * 2014-03-12 2017-08-22 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Амидные соединения, способы получения, применение в качестве средств для лечения и профилактики заболеваний, вызываемых рнк-содержащими вирусами
US10053671B2 (en) 2014-06-20 2018-08-21 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
AU2015252119A1 (en) 2014-11-07 2016-05-26 Takeda Vaccines, Inc. Hand, foot, and mouth vaccines and methods of manufacture and use thereof
AR102547A1 (es) 2014-11-07 2017-03-08 Takeda Vaccines Inc Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso
US10633422B2 (en) 2015-06-01 2020-04-28 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA
EP3313439A2 (en) 2015-06-26 2018-05-02 Seqirus UK Limited Antigenically matched influenza vaccines
WO2017007839A1 (en) 2015-07-06 2017-01-12 Wisconsin Alumni Research Foundation (Warf) Improved influenza virus replication for vaccine development
US10416171B2 (en) 2015-07-07 2019-09-17 Seqirus UK Limited Influenza potency assays
US11197925B2 (en) 2016-02-19 2021-12-14 Wisconsin Alumni Research Foundation (Warf) Influenza B virus replication for vaccine development
WO2019084310A1 (en) 2017-10-25 2019-05-02 Yoshihiro Kawaoka HAS RECOMBINANT INFLUENZA VIRUSES STABILIZED FOR EGG REPLICATION
MX2020004151A (es) 2017-10-30 2020-08-13 Takeda Pharmaceuticals Co Detergentes compatibles con el medio ambiente para la inactivacion de virus envueltos en lipidos.
CA3081586A1 (en) 2017-11-03 2019-05-09 Takeda Vaccines, Inc. Zika vaccines and immunogenic compositions, and methods of using the same
WO2020033527A2 (en) 2018-08-07 2020-02-13 Wisconsin Alumni Research Foundation (Warf) Recombinant biologically contained filovirus vaccine
EP3840780A1 (en) 2018-08-20 2021-06-30 Wisconsin Alumni Research Foundation Vectors for eliciting immune responses to non-dominant epitopes in the hemagglutinin (ha) protein
US20210324483A1 (en) * 2018-10-15 2021-10-21 Regenxbio Inc. Method for measuring the infectivity of replication defective viral vectors and viruses
WO2020167432A2 (en) 2019-01-23 2020-08-20 Yoshihiro Kawaoka Mutations that confer genetic stability to additional genes in influenza viruses
EP3921413A1 (en) 2019-02-08 2021-12-15 Wisconsin Alumni Research Foundation (WARF) Humanized cell line
WO2020223699A1 (en) 2019-05-01 2020-11-05 Wisconsin Alumni Research Foundation (Warf) Improved influenza virus replication for vaccine development
AU2020269164B2 (en) 2019-05-08 2024-04-04 Takeda Vaccines, Inc. Inactivated virus compositions and Zika vaccine formulations
WO2021041624A2 (en) 2019-08-27 2021-03-04 Yoshihiro Kawaoka Recombinant influenza viruses with stabilized ha for replication in eggs
BR112022009545A2 (pt) 2019-11-18 2022-10-11 Seqirus Pty Ltd Método para produzir vírus influenza recombinantes
US11739303B2 (en) * 2020-01-24 2023-08-29 Wisconsin Alumni Research Foundation (Warf) Recombinant influenza viruses with stabilized NA
WO2021195410A1 (en) 2020-03-25 2021-09-30 Wisconsin Alumni Research Foundation (Warf) Recombinant multivalent influenza viruses
US20240139306A1 (en) * 2021-03-01 2024-05-02 Iowa State University Research Foundation, Inc. Methods and compositions for detecting and producing porcine morbillivirus and vaccines thereof
CN114107392A (zh) * 2021-11-22 2022-03-01 昆明理工大学 一种cvb5病毒类病毒样颗粒的制备方法
WO2023154043A1 (en) 2022-02-09 2023-08-17 Takeda Vaccines, Inc. Zika vaccines and immunogenic compositions, and methods of using the same

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4193991A (en) 1978-12-20 1980-03-18 Cornell Research Foundation, Inc. Canine parvovirus vaccine
EP0261955A3 (en) * 1986-09-26 1989-06-07 E.I. Du Pont De Nemours And Company Process for immobilization of dna
US6284492B1 (en) * 1988-02-26 2001-09-04 Large Scale Biology Corporation Recombinant animal viral nucleic acids
CA2054228A1 (en) 1990-10-30 1992-05-01 Masaharu Oki Muramyldipeptide derivatives and influenza vaccine comprising the derivatives
JPH0813753B2 (ja) * 1992-05-22 1996-02-14 株式会社微生物化学研究所 牛伝染性鼻気管炎ウイルス感染症、牛ウイルス性下痢−粘膜病ウイルス感染症、パラインフルエンザ３型ウイルス感染症、牛ｒｓウイルス感染症および牛アデノ７型ウイルス感染症５種混合生ワクチン
IL103939A (en) * 1992-12-01 1996-09-12 Abic Ltd An anti-DBI vaccine in birds containing attenuated live DBI virus
CA2156525A1 (en) 1993-02-19 1994-09-01 Susan Dillon Influenza vaccine compositions containing 3-o-deacylated monophosphoryl lipid a
DE4311580C1 (de) * 1993-04-12 1994-08-18 Werner Prof Dr Med Reutter Glycoproteine, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Mittel
US5824536A (en) * 1994-08-23 1998-10-20 St. Jude Children's Research Hospital Influenza virus replicated in mammalian cell culture and vaccine production
EP0791055B1 (en) 1994-11-10 2012-01-25 Baxter Healthcare S.A. Method for producing biologicals in protein-free culture
US6146873A (en) * 1994-11-10 2000-11-14 Baxter Aktiengesellschaft Production of orthomyxoviruses in monkey kidney cells using protein-free media
GB9500788D0 (en) 1995-01-16 1995-03-08 Medeva Holdings Bv Vaccine compositions
DE19612967A1 (de) * 1996-04-01 1997-10-02 Behringwerke Ag Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren
DE19612966B4 (de) 1996-04-01 2009-12-10 Novartis Vaccines And Diagnostics Gmbh & Co. Kg MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren
TW570803B (en) 1997-04-09 2004-01-11 Duphar Int Res Influenza vaccine
JPH1175833A (ja) * 1997-06-23 1999-03-23 Chemo Sero Therapeut Res Inst トリレオウイルスの調製法
GB9725084D0 (en) 1997-11-28 1998-01-28 Medeva Europ Ltd Vaccine compositions
CN1309708A (zh) 1997-12-11 2001-08-22 萨斯喀彻温大学 来源于猪的断奶后多系统消耗综合症病毒
GB9804632D0 (en) * 1998-03-05 1998-04-29 Cantab Pharma Res Virus preparations and methods
AT408615B (de) 1998-09-15 2002-01-25 Immuno Ag Neue influenzavirus-impfstoffzusammensetzung
US6855544B1 (en) * 1999-04-15 2005-02-15 Crucell Holland B.V. Recombinant protein production in a human cell
GB9923176D0 (en) 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
EP1103610A1 (en) * 1999-11-26 2001-05-30 Introgene B.V. Production of vaccines from immortalised mammalian cell lines
US7192759B1 (en) * 1999-11-26 2007-03-20 Crucell Holland B.V. Production of vaccines
DOP2000000109A (es) * 1999-12-23 2002-08-30 Gerald Kleymann Derivados de tiazolilamida
TWI228420B (en) 2001-05-30 2005-03-01 Smithkline Beecham Pharma Gmbh Novel vaccine composition
DE10144906B4 (de) 2001-09-12 2013-11-28 Novartis Vaccines And Diagnostics Gmbh Verfahren zur großtechnischen Herstellung von Impfstoffen
DE10144903A1 (de) * 2001-09-12 2003-03-27 Chiron Behring Gmbh & Co Vermehrung von Viren in Zellkultur
FR2836924B1 (fr) 2002-03-08 2005-01-14 Vivalis Lignees de cellules aviaires utiles pour la production de substances d'interet
KR101229202B1 (ko) * 2002-04-26 2013-02-01 메디뮨 엘엘씨 인플루엔자 바이러스의 생산을 위한 다중 플라스미드 시스템
DE10221836A1 (de) * 2002-05-16 2003-12-04 Lohmann Animal Health Gmbh Attenuierung von Metapneumovirus
EP2287288B1 (en) * 2002-07-09 2012-11-07 Baxter International Inc. Animal protein free media for cultivation of cells
JP3957188B2 (ja) * 2002-10-25 2007-08-15 ▲あき▼夫 友田 抗ウィルス剤
CA2514653A1 (en) 2003-01-30 2004-08-12 Medimmune, Inc. Uses of integrin alphavbeta3 antagonists
CA2523319A1 (en) * 2003-04-25 2004-11-11 Medimmune Vaccines, Inc. Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences and methods for propagating virus
EP1528101A1 (en) 2003-11-03 2005-05-04 ProBioGen AG Immortalized avian cell lines for virus production
JP2008512443A (ja) * 2004-09-09 2008-04-24 カイロン ベーリング ゲーエムベーハー アンド カンパニー インフルエンザワクチンに関連する潜在的医原性リスクの減少
CA2690668C (en) 2007-06-14 2014-08-19 The Board Of Regents For Oklahoma State University Vaccines containing canine parvovirus genetic variants

Also Published As

Publication number Publication date
PL2236155T3 (pl) 2012-10-31
US8119337B2 (en) 2012-02-21
HK1144374A1 (en) 2011-02-18
JP2015205929A (ja) 2015-11-19
EP2236155A1 (en) 2010-10-06
PL1789084T3 (pl) 2011-05-31
WO2006027698A1 (en) 2006-03-16
US10155932B2 (en) 2018-12-18
DE12193096T1 (de) 2013-07-25
PL2578229T3 (pl) 2014-01-31
DK1789084T3 (da) 2011-01-10
SI1789084T1 (sl) 2011-03-31
US8460914B2 (en) 2013-06-11
HRP20120640T1 (hr) 2012-08-31
CA2579859C (en) 2015-12-08
CY1111180T1 (el) 2015-06-11
US20090081252A1 (en) 2009-03-26
EP2179744B1 (en) 2010-12-01
US10954493B2 (en) 2021-03-23
SI2236155T1 (sl) 2012-09-28
PT1789084E (pt) 2011-02-22
JP2008512443A (ja) 2008-04-24
US20190078060A1 (en) 2019-03-14
ES2432655T3 (es) 2013-12-04
ES2357752T3 (es) 2011-04-29
HK1105364A1 (en) 2008-02-15
SI2578229T1 (sl) 2013-10-30
EP2578229A1 (en) 2013-04-10
PT2578229E (pt) 2013-09-27
US20130129782A1 (en) 2013-05-23
EP1789084A1 (en) 2007-05-30
RS51721B (en) 2011-10-31
JP2019210292A (ja) 2019-12-12
ATE489965T1 (de) 2010-12-15
US20130122487A1 (en) 2013-05-16
RS52400B (en) 2013-02-28
DE602005025170D1 (de) 2011-01-13
EP2471551B1 (en) 2017-02-01
CY1111208T1 (el) 2015-06-11
EP2471551A3 (en) 2012-11-14
DK2236155T3 (da) 2012-08-13
HRP20130962T1 (hr) 2013-12-06
PT2179744E (pt) 2011-03-09
PL2179744T3 (pl) 2011-09-30
ATE488248T1 (de) 2010-12-15
SI2179744T1 (sl) 2011-04-29
JP2012025784A (ja) 2012-02-09
CA2890962A1 (en) 2006-03-16
EP2179744A1 (en) 2010-04-28
DE602005024827D1 (de) 2010-12-30
JP2017057209A (ja) 2017-03-23
US9358280B2 (en) 2016-06-07
ES2386272T3 (es) 2012-08-16
PT2236155E (pt) 2012-07-19
US9220768B2 (en) 2015-12-29
EP2471551A2 (en) 2012-07-04
JP2011207911A (ja) 2011-10-20
JP2013100358A (ja) 2013-05-23
EP2578229B1 (en) 2013-07-10
CY1113225T1 (el) 2016-04-13
RS51665B (en) 2011-10-31
HRP20110007T1 (hr) 2011-04-30
EP1789084B1 (en) 2010-11-17
DK2179744T3 (da) 2011-01-31
ES2357747T3 (es) 2011-04-29
EP2236155B1 (en) 2012-05-16
US20160251631A1 (en) 2016-09-01
DK2578229T3 (da) 2013-10-07
US20120034600A1 (en) 2012-02-09
CA2579859A1 (en) 2006-03-16

Similar Documents

Publication Publication Date Title
HRP20100673T1 (hr) Smanjivanje potencijalnih jatrogenskih rizika povezanih s cjepivima protiv gripe
Infl et al. WHO manual on animal influenza diagnosis and surveillance
JP2008512443A5 (hr)
Li et al. Occurrence and transmission of Newcastle disease virus aerosol originating from infected chickens under experimental conditions
Pastoret Human and animal vaccine contaminations
Moniwa et al. Experimental foot-and-mouth disease virus infection in white tailed deer
Banach et al. Human airway epithelial cell culture to identify new respiratory viruses: coronavirus NL63 as a model
Weesendorp et al. Quantification of classical swine fever virus in aerosols originating from pigs infected with strains of high, moderate or low virulence
Velayudhan et al. Human metapneumovirus in turkey poults
CN102965344B (zh) 用细胞系生产鸡传染性支气管炎病毒与疫苗
Cliquet et al. The fluorescent antibody virus neutralization test
Gueriche et al. The etiological role of the parainfluenza-3 virus in the respiratory pathology of young cattle
CN106591177A (zh) 一种山羊支原体山羊肺炎亚种低血清高效培养基及其制备方法
CN113049816B (zh) 一种新城疫病毒滴度的测定方法
Wang et al. Pathogenicity, immunogenicity, and protective ability of an attenuated SARS-CoV-2 variant with a deletion at the S1/S2 junction of the spike protein
Namroodi et al. Frequency and antimicrobial resistance pattern of Salmonella Spp in asymptomatic rural dogs
TWI300807B (en) Attenuated avian infectious bronchitis virus vaccines
Manzoor et al. Pathotyping of Newcastle disease virus using multiplex reverse transcription polymerase chain reaction and pathological studies in naturally infected broiler chicks
Hostnik et al. Control of equine arteritis virus (EAV) on stud farm.
JP6174857B2 (ja) 外来物質試験
TWI309563B (hr)
EP3076993A1 (en) Process for preparing influenza vaccines
Mohammed et al. Replication of infectious bronchitis virus in the chicken mesenchymal stem cells
Cheng Innovator of in vitro virus culture—Dr. Chen-Hsiang Huang
Sayed et al. Shedding pattern of classical and variant strain of IB challenge virus in SPF and commercial layer vaccinated chicken with trivalent vaccine containing H9N2 AI, LaSota, classical M41 and var 2 IB viruses at 1, 3 and 7 months post vaccination